KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Common Equity (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Common Equity data on record, last reported at $582.5 million in Q3 2025.

  • For Q3 2025, Common Equity rose 14.58% year-over-year to $582.5 million; the TTM value through Sep 2025 reached $582.5 million, up 14.58%, while the annual FY2024 figure was $482.8 million, 25.64% down from the prior year.
  • Common Equity reached $582.5 million in Q3 2025 per EBS's latest filing, up from $536.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.6 billion in Q4 2021 and bottomed at $386.3 million in Q2 2024.
  • Average Common Equity over 5 years is $993.6 million, with a median of $827.4 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 41.68% in 2021, then plummeted 59.66% in 2024.
  • A 5-year view of Common Equity shows it stood at $1.6 billion in 2021, then dropped by 13.89% to $1.4 billion in 2022, then plummeted by 53.21% to $649.3 million in 2023, then fell by 25.64% to $482.8 million in 2024, then rose by 20.65% to $582.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $582.5 million in Q3 2025, $536.2 million in Q2 2025, and $552.7 million in Q1 2025.